What a buyer sees
PHARMACY CARE PLUS LIMITED
Other human health activities · Cheadle Hulme · 06521783
100staff · FY2023
18years trading
65oldest owner on file
£641kcash at bank
Your turnover is on public record
filed£13Mfor the year to 2023
Unusual at this size, and it works in your favour: a buyer is reading your number rather than guessing at one.
What your filings show moving
Staff100
2021116 → 1002023
Cash at bank£641k
2021£1.6M → £641k2023
How you sit in your trade
slowest tenth typical fastest tenth youSales per employee£128,456in the top quarter
£29,055£51,789£189,005
Debtor daysdays7below almost all
122972
Creditor daysdays42
81339
Stock daysdays21in the middle half
723151
Each spread is companies in the same trade and size that did publish a turnover. Creditor days are shown but not marked: neither end of that one is plainly good.
What a buyer would ask 2
- The newest accounts on file are 32 months oldAnyone looking at the company today is reading a year that has already ended. Whatever has improved since is invisible.
- No website on file against the companyThe first thing anyone does with a company number is look for the business behind it. Finding nothing is its own answer.
What a buyer would like 3
- Sales per employee better than three quarters of your tradeYours is 128,456 against 51,788 for the middle of 109 comparable companies.
- Debtor days better than three quarters of your tradeYours is 7 against 29 for the middle of 83 comparable companies.
- A board that has been together ten years or moreContinuity a buyer does not have to take on trust.
What the register says
Owners
- 59since 2016
- 65since 2016
Directors
- 65since 2008
- 59since 2008
- since 2010
| Year to | Turnover | Staff | Cash |
|---|---|---|---|
| 2023-12-31 | £13M | 100 | £641k |
| 2022-12-31 | £21M | 104 | £773k |
| 2021-06-30 | £13M | 116 | £1.6M |
A rough bracket, and why it is only that
0.6–1.3× sales£7.7M£17M
The turnover range is fitted on UK companies that did file one. The multiple is a published sector average from Dutch mid-market deals, not from your own numbers and not from your own market. Treat this as the opening bracket of a conversation, not a valuation.